NEURVANA

Dr. Richard Clark Kaufman
NEURVANA Chief Science Officer, Author, Biogerontologist

Ritalin’s connection to sudden death is only one of many problems from Ritalin  stimulant therapy for ADD/ADHD.

• Ritalin can disrupt growth hormone production and neurotransmitter systems. Studies show risk of long term and permanent changes in brain chemistry from Ritalin.
• Besides insomnia and nervousness, other adverse reactions to Ritalin published in the PDR include hypersensitivity (including skin rash, fever, dermatitis), anorexia, nausea, dizziness, palpitations, headache, drowsiness, blood pressure changes, tachycardia, angina, arrhythmia, abdominal pain, weight loss and toxic psychosis.

Published research has found the long-term value of Ritalin disappointing. A review all the studies published over the last twenty years on the effects of stimulant medication for ADD/ADHD found that the Ritalin only temporarily managed the symptoms. Children who took stimulant medication over several years did just as poorly in later life as the group of hyperactive children who took no medication.

There are safer alternatives to stimulant drug’ therapy for ADD/ADHD in children and adults. Bear in mind, ADD/ADHD are multifactorial disorders. The trace amine beta-phenylethylamine (PEA) is a natural brain stimulant and neuromodulatory produced by the human brain that plays a pivotal role in neuronal processes that produce ADD/ADHD. For example, PEA levels are significantly lower in children with ADHD. PEA may safely be ingested as a dietary supplement and incorporated into treatment protocols for ADD/ADHD, attention disorders, learning problems, and other disorders.